No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib

NCT04874207Phase 4Completed110 enrolled

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

NCT03564938Phase 4Completed100 enrolled

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib

NCT02800330Phase 4Completed31 enrolled

View all 3 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

The efficacy of regorafenib combined with PD-1/PD-L1 inhibitor in advanced or metastatic colorectal cancer: A single arm meta-analysis.

Yang Fan, Li Dandan, Li Baozhong et al. · Medicine (Baltimore) · 2026

PMID: 41578466Meta-Analysis

The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies.

Yang Fan, Mao Ying, Huang Hanyu et al. · Front Immunol · 2025

PMID: 40510355Meta-AnalysisFull text (PMC)

Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.

Han Yuanhang, Xie Jiangtao, Wang Yuyang et al. · BMC Cancer · 2025

PMID: 39972254Meta-AnalysisFull text (PMC)

Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Shen Yunzhi, Bai Yu · Medicine (Baltimore) · 2025

PMID: 39854748Meta-AnalysisFull text (PMC)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Regorafenib in the Treatment of Metastatic Colorectal Cancer.

Liang Bingjun, Tang Ming, Huang Chao et al. · J Gastrointest Cancer · 2024

PMID: 39710828Meta-Analysis

An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review.

Darmadi Darmadi, Sungkar Taufik, Pakpahan Cennikon et al. · Acta Med Acad · 2024

PMID: 38984699Meta-AnalysisFull text (PMC)

Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Xu Huilin, Cao Dedong, Zhou Dingjie et al. · BMC Cancer · 2023

PMID: 37858207Meta-AnalysisFull text (PMC)

Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.

Yang Shuheng, Zhou Yadong, Zeng Lei · Adv Clin Exp Med · 2023

PMID: 37140014Meta-Analysis

KDR genetic predictor of toxicities induced by sorafenib and regorafenib.

Quintanilha Julia C F, Geyer Susan, Etheridge Amy S et al. · Pharmacogenomics J · 2022

PMID: 35484400Meta-AnalysisFull text (PMC)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.

Chen Jianxin, Wang Junhui, Xie Fangwei · Medicine (Baltimore) · 2021

PMID: 34559096Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Regorafenib (substance)
SNOMED CT: 702804006
UMLS CUI: C2980094
RxNorm CUI: 1312397

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.